---
title: "Fresenius Medical Care Files Q1 2026 Interim Report and Affirms Internal Control Compliance"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285228484.md"
description: "Fresenius Medical Care (FMS) filed a Form 6-K in May 2026, detailing its Q1 2026 financial results and internal control compliance. The report includes segment structures, performance measurement, and a shift in Value-Based Care functions. CEO Helen Giza certified the report under Sarbanes-Oxley, emphasizing regulatory compliance. Analysts rate FMS stock as a Hold with a $26.00 price target, reflecting moderate fundamentals and a cautious outlook for 2026. Fresenius specializes in healthcare for chronic kidney disease, manufacturing dialysis equipment and operating treatment clinics."
datetime: "2026-05-05T14:58:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285228484.md)
  - [en](https://longbridge.com/en/news/285228484.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285228484.md)
---

# Fresenius Medical Care Files Q1 2026 Interim Report and Affirms Internal Control Compliance

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Fresenius Medical Care ( (FMS) ) has shared an announcement.

Fresenius Medical Care filed a Form 6-K in May 2026 providing an interim report on its financial condition and results of operations for the three months ended March 31, 2026 and 2025. The filing outlines segment structures, reporting practices, and the allocation of corporate and functional costs, including a shift from April 2026 to allocate certain Value-Based Care support functions into global areas.

The company also detailed how it measures performance, including constant currency analysis and distinct treatment of value- and risk-based care revenues under IFRS 15 and IFRS 17, underscoring governance around segment reporting and internal controls. On May 5, 2026, CEO Helen Giza certified under Sarbanes-Oxley that the report fairly presents the firm’s financial results and that disclosure controls and internal control over financial reporting have been designed, evaluated, and maintained, signaling continued emphasis on regulatory compliance and transparency for investors.

The most recent analyst rating on (FMS) stock is a Hold with a $26.00 price target. To see the full list of analyst forecasts on Fresenius Medical Care stock, see the FMS Stock Forecast page.

**Spark’s Take on FMS Stock**

According to Spark, TipRanks’ AI Analyst, FMS is a Neutral.

The score reflects moderate fundamentals with improving profitability and a stable balance sheet but weakening growth/cash-flow trends, a cautious 2026 outlook with meaningful headwinds despite strong execution initiatives, and a supportive valuation (modest P/E and solid dividend) alongside neutral-to-soft technical momentum.

To see Spark’s full report on FMS stock, click here.

**More about Fresenius Medical Care**

Fresenius Medical Care AG is a Germany-based healthcare company specializing in products and services for patients with chronic kidney disease and end-stage renal disease. Through its Care Enablement, Care Delivery, and Value-Based Care segments, it manufactures dialysis equipment and supplies, operates treatment clinics, and runs value-based kidney care programs focused on clinical outcomes and cost efficiency.

**Average Trading Volume:** 568,222

**Technical Sentiment Signal:** Sell

**Current Market Cap:** $13.2B

### Related Stocks

- [FMS.US](https://longbridge.com/en/quote/FMS.US.md)
- [FME.DE](https://longbridge.com/en/quote/FME.DE.md)

## Related News & Research

- [Fresenius Medical Care Refocuses Symvess Rights And Vascular Access Ambitions](https://longbridge.com/en/news/284990720.md)
- [09:39 ETParkinson's Foundation Invests Nearly $600K in Innovative Care Grants](https://longbridge.com/en/news/286923742.md)
- [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md)
- [NephroPlus sharpens global dialysis push as overseas business grows](https://longbridge.com/en/news/287024448.md)
- [FMCG sector likely to see 5% volume growth in 2026: Worldpanel by Numerator](https://longbridge.com/en/news/287028803.md)